

India got cheap Ozempic. No one knows how to sell it
Ozempic went off-patent in India this year, and everyone from Novo Nordisk to Nestlé has rushed in expecting a billion-dollar market. Instead, growth has already stalled, and the reason isn't price. It's culture. While Hollywood joked about Ozempic on late-night TV and Serena Williams advertised a GLP-1 program for a…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Daybreak
See all episodes →
India cut the tax on Scotch. Customs is now asking: what counts as Scotch?

Hospitals won’t pay for India’s medical inflation and insurers can’t

Why global betting giants are paying Indian data scouts to see games before bettors
Similar episodes from other shows
More like Daybreak →
Semaglutide Goes Generic: Big Pharma’s Moat Breaks

Can India break this Pharma Monopoly?

Can India become the pharmacy for weight-loss drugs?

Trillion Dollar Shot, Episode 2: Bank Breakers
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.